Novavax is preparing to have its XBB.1.5 Covid-19 vaccine ready for market by the end of September, calling it its “highest priority.” However, the company is still in the middle of the filing process with the FDA.
The company said Tuesday in its second-quarter earnings report that it plans to have its updated Covid vaccine ready for the fall vaccination season.
“We submitted the preclinical and clinical packages, and we’re going to complete that file this month,” Novavax R&D chief Filip Dubovsky said on an investor call.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.